Pharma and Biotech IP 2020

Pharma and Biotech 2020 Web Banners_950x250

The life sciences are in a period of dramatic change and innovation. Developments in new technologies, such as cell therapies and gene editing, are challenging traditional IP strategies and business models.

IAM’s fourth annual Pharma and Biotech IP will bring together leading in-house practitioners and expert counsel to discuss next-generation strategies for protecting and exploiting cutting-edge innovation.

Attendees will:

  • Learn about recent developments, key decisions and the latest IP challenges from Europe, the United States and China
  • Understand how IP strategies are adapting and how to avoid pitfalls and costly mistakes
  • Determine what the convergence between life sciences and tech means for you and what lessons can be learned from high-tech innovators
  • Gain best practices for protecting cutting-edge technologies – from personalised medicines to gene and cell therapies
  • Shed light on how IP can and should be used as a part of a wider value creation strategy

Keynote speaker for 2020:

  • Sir Robin Jacob, Sir Hugh Laddie Chair of Intellectual Property Law, UCL

Speakers for 2020 include:

  • Alvin (Jun) Deng, Head of IP, Novozymes China
  • Ben Goodger, General Counsel, ASLAN Pharmaceuticals
  • James Horgan, Assistant Managing Counsel, Merck Sharp & Dohme
  • Hannes Iserentant, IP Director, Celyad
  • Gareth Jones, Vice President, IP, BenevolentAI
  • Mark Kokes, Chief IP Officer, Nantworks
  • Sergei Kurkin, Director, Senior Patent Counsel, UCB
  • Florian Leverve, Head, IP, Pharnext
  • Alison McGhee, Vice President, IP, F-Star Biotechnology
  • Maria Nichol, Vice President, IP, Galapagos
  • Marion Rees, Vice President, IP and Legal Affairs, Adiga Life Sciences
  • Dean Thomas, Global Head of IP, Ichnos Sciences

For more information, please contact

Camille Etroit

2 December, 2019